Cure8 research brief
The study shows functional differences in how Crohn’s versus healthy fecal microbiota ferment substrates, with CD cultures making less beneficial butyrate and more ethanol/amino acids. That could inform future diagnostics or microbiome-focused therapies for IBD if validated clinically.
Researchers, clinicians interested in microbiome diagnostics or therapies, and patients/advocates tracking microbiome research.
Researchers grew fecal microbial communities from people with Crohn’s disease (CD) and healthy individuals in standardized in vitro batch cultures using glucose or an acetate+lactate mix as substrates.
Cultures from healthy donors converted lactate+acetate to butyrate (and other C2–C6 organic acids), whereas CD-derived cultures showed impaired conversion with lower butyrate, valerate and caproate and higher ethanol and certain amino acids.
The study links these functional differences to lower abundance of typical butyrate-producing commensals (for example, Faecalibacterium prausnitzii, Eubacterium rectale, Coprococcus catus) and an enrichment of genes for ethanol and amino-acid biosynthesis—with E. coli highlighted for metabolic versatility.
Authors conclude that fermentation patterns in these controlled batch cultures can distinguish CD-associated dysbiosis from healthy microbiota and suggest potential diagnostic applications and microbiome-restoration implications, while noting further validation is needed.
This is an in vitro laboratory study (abstract-level summary). Results reflect controlled batch cultures and need further clinical validation; it does not show patient outcomes or tested interventions.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Institute of Biochemistry and Biophysics Polish Academy of Sciences - MG-2/21-18
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.
This research links a bacterial surface capsule to how well a gut microbe colonizes the intestine and to lower inflammatory responses in mouse models, which may help explain strain differences seen in Crohn’s disease and...
The study identifies a gut bacterial metabolite that appears to reduce intestinal inflammation through SIRT1 stabilization and macrophage metabolic reprogramming — a potential new biological pathway relevant to Crohn’s...
